Development of an inactivated vaccine candidate for SARS-CoV-2
Sinovac Biotech · Chinese Academy of Medical Sciences & Peking Union Medical College · +8 more institutions
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against…
Citation impact
- FWCI
- 35.19
- Percentile
- 100%
- References
- 24
Authors
36- QGQiang GaoCorresponding
Sinovac Biotech
- LBLinlin BaoCorresponding
Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Laboratory Animal Science
- HMHaiyan MaoCorresponding
Zhejiang Center for Disease Control and Prevention
- LWLin WangCorresponding
Sinovac Biotech
- KXKangwei XuCorresponding
National Institutes for Food and Drug Control
Topics & keywords
- Virology
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Medicine
- Macaque
- Virus
- Attenuated vaccine
- Coronavirus disease 2019 (COVID-19)
- Pharynx
- Good health and well-being